Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioqual Inc. stock logo
BIOQ
Bioqual
$44.25
$47.02
$44.25
$72.50
$39.58M-0.1112 shsN/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
$3.19
$1.62
$10.97
$5K0.7271,922 shs115 shs
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
$0.11
$0.00
$0.84
N/A-1536.271,618 shsN/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioqual Inc. stock logo
BIOQ
Bioqual
0.00%0.00%-1.67%-20.98%-38.97%
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
0.00%0.00%0.00%0.00%-50.00%
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
0.00%0.00%0.00%0.00%-99.99%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bioqual Inc. stock logo
BIOQ
Bioqual
N/AN/AN/AN/AN/AN/AN/AN/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
N/AN/AN/AN/AN/AN/AN/AN/A
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bioqual Inc. stock logo
BIOQ
Bioqual
0.00
N/AN/AN/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
0.00
N/AN/AN/A
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bioqual Inc. stock logo
BIOQ
Bioqual
$58.59M0.67N/AN/AN/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
$260K0.00N/AN/A$0.87 per share0.00
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bioqual Inc. stock logo
BIOQ
Bioqual
$480K-$2.39N/AN/A-4.34%-5.82%-3.79%N/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
-$2.40MN/A0.00N/AN/AN/A-32.84%-31.29%N/A
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
-$36.06MN/A0.00N/AN/AN/AN/AN/AN/A

Latest BIOQ, CBLI, and ELOX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/11/2025Q3 2025
Bioqual Inc. stock logo
BIOQ
Bioqual
N/A$1.05N/A$1.05N/A$14.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bioqual Inc. stock logo
BIOQ
Bioqual
$0.501.13%N/AN/A N/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
N/AN/AN/AN/AN/A
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bioqual Inc. stock logo
BIOQ
Bioqual
N/A
5.08
5.08
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
N/A
45.93
45.93
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Bioqual Inc. stock logo
BIOQ
Bioqual
N/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
5.09%
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
2.90%

Insider Ownership

CompanyInsider Ownership
Bioqual Inc. stock logo
BIOQ
Bioqual
39.24%
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
1.03%
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
20.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bioqual Inc. stock logo
BIOQ
Bioqual
114890,000543,000Not Optionable
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
415.48 millionN/ANot Optionable
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
303.14 million2.51 millionNot Optionable

Recent News About These Companies

Eloxx Pharmaceuticals Inc (ELOX)
Vertex Pharmaceuticals Inc.
Eloxx Pharmaceuticals, Inc. (ELOX)

New MarketBeat Followers Over Time

Bioqual stock logo

Bioqual OTCMKTS:BIOQ

$44.25 0.00 (0.00%)
As of 07/1/2025

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.

Cleveland BioLabs stock logo

Cleveland BioLabs NASDAQ:CBLI

Cytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.

Eloxx Pharmaceuticals stock logo

Eloxx Pharmaceuticals NASDAQ:ELOX

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.